Amneal Pharmaceuticals registers Phase 3 trial of testosterone cypionate auto-injector
The Phase 3 study, recruiting 190 participants, was first posted on ClinicalTrials.gov on October 27, 2026, with primary completion projected for March 31, 2027. It aims to evaluate the safety, efficacy, and usability of a weekly subcutaneous testosterone cypionate auto-injector in adult males with hypogonadism.
Primary source
ClinicalTrials.gov registry record, October 27, 2026
Safety and Efficacy of Weekly Testosterone Cypionate Auto-Injector in Men With Hypogonadism
Read the source: Safety and Efficacy of Weekly Testosterone Cypionate Auto-Injector in Men With Hypogonadism clinicaltrials.gov
Machine-summarized from the source above; not independently reported. How we use automation